CAM
NUVB icon

Cormorant Asset Management’s Nuvation Bio NUVB Stock Holding History

Cormorant Asset Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-234,445
Closed -$2.45M – 119
2021
Q1 		$2.45M Buy
+234,445
New +$2.62M 0.05% 105

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Cormorant Asset Management's NUVB Position: Q2 2021 in Review

Cormorant Asset Management sold out of Nuvation Bio (NUVB) in Q2 2021, closing a stake of 234,445 shares — an estimated $2.45M sold.

Cormorant Asset Management first reported a position in NUVB in Q1 2021 and held it in 1 quarter. The position peaked at $2.45M in Q1 2021. 99 funds tracked by Wall St. Rank hold NUVB as of Q2 2021.

  • Cormorant Asset Management reported no remaining Nuvation Bio position as of Q2 2021 after selling out during the quarter.
  • Cormorant Asset Management sold 234,445 Nuvation Bio shares in Q2 2021, an estimated $2.45M.
  • Cormorant Asset Management first reported a position in Nuvation Bio in Q1 2021 and held it in 1 quarter.
  • Cormorant Asset Management's Nuvation Bio position peaked at $2.45M in Q1 2021.
  • 99 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2021.

Based on Cormorant Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.